-
Molecular RT-LAMP Detection of COVID-19 & Influenza A/B RNA
-
Differentiates SARS-CoV-2, Influenza A, & Influenza B in a Single Test
-
Provides Lab-Quality Results in Approximately 20 Minutes
-
Uses Nasal Swab Specimens
-
Authorized for CLIA-Waived Point-of-Care
-
Optional Metrix Reader Device Inclusion .
The Sekisui Diagnostics Metrix COVID/Flu A&B Rapid Test Kit is a rapid molecular diagnostic assay that is used for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B RNA from nasal swab specimens. It utilizes reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology, delivering lab-quality molecular results in approximately 20 minutes.
✔ MOLECULAR RT-LAMP TESTING | ✔ 20-MINUTE RESULTS | ✔ COVID-19 & FLU A/B DETECTION
ADVANCED MOLECULAR RESPIRATORY TESTING
SIMULTANEOUS VIRAL RNA DETECTION: Qualitatively detects and differentiates RNA from SARS-CoV-2, Influenza A, and Influenza B from a single nasal swab specimen collected from individuals with signs and symptoms of respiratory tract infection.
RT-LAMP MOLECULAR TECHNOLOGY: Utilizes reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology to amplify and detect viral RNA, providing rapid molecular testing without conventional laboratory PCR instrumentation.
LAB-QUALITY RESULTS: Delivers lab-quality molecular results in approximately 20 minutes, enabling timely clinical decision-making in both professional healthcare and authorized home testing environments.
STREAMLINED MOLECULAR WORKFLOW
METRIX READER (GEN 2) REQUIRED: Designed exclusively for use with the Metrix Reader (Gen 2), which performs automated amplification, analysis, and result interpretation.
COMPLETE TEST COMPONENTS: Each individual test includes a Cap, Collector, Nasal Swab, Sensor, and Test Instructions. The 25-pack provides all consumables required to perform 25 molecular tests.
AUTHORIZED FOR PROFESSIONAL & HOME USE: Authorized for use in CLIA-waived healthcare settings and for non-prescription home use under FDA Emergency Use Authorization (EUA) when performed according to the manufacturer's Instructions for Use.
VERSATILE CONFIGURATIONS: You may buy 1 box of 25 tests (MTRX-C19+FLU-25PK), or the package with 2 boxes of the test kit together with the Metrix Reader device (MTRX-C19+FLU-B1).
The Sekisui Diagnostics Metrix COVID/Flu A&B Rapid Test Kit provides rapid molecular detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B RNA, combining a streamlined workflow, and approximately 20-minute lab-quality results, to support timely clinical decision-making in both professional and authorized home testing environments.
**FDA Disclaimer: This combination test is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for use by authorized laboratories. It is authorized for the rapid detection of proteins from SARS-CoV-2, Influenza A and B, and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
WARNING: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.
